Histone Deacetylase Inhibitors Market Trends

Growth Drivers 

• Increasing investment and interest in extensive explorations: The growing research & development activities for creating advanced drugs are believed to fuel the histone deacetylase inhibitors market. The discovery of new indications from these medicines has become a trend to expand the field of applications and a key tactic of designing novel combination therapies in this sector. For instance, in June 2022, Celleron Therapeutics shared promising results from the phase II clinical trial on zabadinostat + nivolumab. The evaluation data demonstrated a 3-year survival rate of 7.3% in late-stage microsatellite stable colorectal cancer. Besides, this merchandise is further gaining traction due to the efforts to improve public access to advanced treatments.
• Integration of tech-based drug discoveries: The utilization of artificial intelligence (AI) and machine learning (ML) in R&D is accelerating the global penetration of the market. Hence, pioneers are forming strategic alliances to mitigate hurdles and limitations related to large-scale and fast-paced medication innovation and production. In this regard, in June 2024, Italfarmaco collaborated with Iktos to escalate the development of next-generation HDAC candidates for a variety of non-oncological diseases. This collaboration allowed the company to possess Iktos’s generative modeling technology and retrosynthesis AI technology platforms, Makya and Spaya, to enhance accuracy, binding site, and synthetic tractability in drug targets.

Challenges 

• Adverse events and expensive development of HDAC inhibitors: The occurrence of several serious and/or severe side effects, including myelosuppression, diarrhea, ventricular arrhythmia, and other cardiac toxicities often cause treatment discontinuation or drug withdrawal. This may raise questions and concerns about the liability of the safety and cost-effectiveness profile of the market. Additionally, this creates delays and uncertainty in acquiring compliance with stringent regulatory criteria. Moreover, the high cost of commercialization and the add-on costs of managing adverse reactions may present an economic barrier among both drug developers and consumers.